FOLD Amicus Corp: Price-to-Projected Revenue Ratio

Amicus Therapeutics - graphic logo of issuer FOLD

Amicus Therapeutics focuses on gene therapy for rare metabolic pathologies, leveraging its patent protection. Revenue stability is guaranteed by patients' lifelong medication adherence. The current forward P/S ratio reflects the business valuation dynamics, with the metric fixed at 7.20. The absence of logistical disruptions in air transport for medications serves as a positive factor for the company's further growth.

Amicus Therapeutics, Inc. - FOLD Market Cap to Expected Sales Ratio (period 07/04/2022 - 05/09/2026)

Summary analytical data breakdowns for Amicus Corp (FOLD)

- market price and analyst price targets:
Price Chart Amicus Therapeutics, Inc.|FOLD - Average Forecast Price
- company stock capitalization data:
Market Value Amicus Corp|FOLD - Total Company Value
- book value of equity indicators:
Book Value per Share Amicus Therapeutics|FOLD - Book Valuation of Business|Market Value to Book Value Ratio amicusrx.com|FOLD - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Amicus Therapeutics|FOLD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Amicus Therapeutics|FOLD - Company Aggregate Debts|Debt to Book Capitalization Ratio Amicus Corp|FOLD - Company Long-Term Liabilities|Company Short-Term Debts Amicus Therapeutics|Quick Ratio amicusrx.com
- financial results and valuation multiples details:
FOLD - Net Income|Future Profit Amicus Therapeutics|FOLD - P/E Multiple|Future Price to Earnings Amicus Pharma|FOLD - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Amicus Corp|FOLD - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Amicus Therapeutics|FOLD - Earnings per share for the last four quarters|Quarterly EPS earnings growth amicusrx.com|FOLD - Earnings per share increase in current year|Earnings growth forecast for next year Amicus Therapeutics
- sales volume and revenue indicators:
FOLD - Company Total Revenue|Company Projected Revenue Amicus Therapeutics, Inc.|FOLD - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Amicus Corp
Fundamental company analysis:FOLD (Amicus Therapeutics, Inc.)
Original product of Amicus Corp

Investors use this ratio to assess the premium paid for future growth, determining the extent to which market value is inflated relative to expected sales. The ratio of market capitalization to projected revenue, reflected through the forward P/S of Amicus Therapeutics (FOLD), confirms the effectiveness of the Amicus Therapeutics business model of outsourcing the production of orphan drugs to external vendors, which minimizes capital expenditures and optimizes business scaling.

Competitors of Amicus Therapeutics (FOLD)

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Forward P/S Multiple ETNB (89bio, Inc.)|Forward P/S Multiple agios.com AGIO|GPCR - Price-to-Projected Revenue Ratio|MiMedx Group Inc (MDXG) - Forward Price-to-Revenue Multiple|RZLT: Forward P/S Multiple|LXRX - Market Cap to Expected Sales Ratio|MBX (MBX Biosciences Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple altimmune.com (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics)|Forward P/S Multiple Sagimet Biosciences, Inc. (SGMT)|Price-to-Projected Revenue Ratio BioAge Labs Inc. BIOA|Market Cap to Expected Sales Ratio Biomea Fusion Corp (BMEA)|QNCX: Forward Price-to-Revenue Multiple|Forward Price to Sales GUTS (fractyl.com)|VTVT (vtvtherapeutics.com) - Forward Price-to-Revenue Multiple|ATPC: Price to Expected Revenue Ratio|PLUR (Pluristem Therapeutics) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|MTNB - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|Forward Price to Sales GLTO|Carmell Corp - Forward P/S Multiple|LUMO - Forward P/S Multiple|Organovo Holdings, Inc. (ONVO) - Price-to-Projected Revenue Ratio|Future Price to Revenue RDUS (radiuspharm.com)